SCHEMBL7213681

SCHEMBL7213681

C1CO[C](C2NCCS2)N1

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27664962 0.73
SCHEMBL5530224 0.72 MAPT (0.42) MAPTTDP1SMN1; SMN2ALDH1A1
SCHEMBL1447816 0.67 MAPT (0.45) MAPTTDP1SMN1; SMN2ALDH1A1
SCHEMBL3807641 0.67 MAPT (0.39) MAPTTDP1SMN1; SMN2ALDH1A1
SCHEMBL27695943 0.67
SCHEMBL27721648 0.63
SCHEMBL235799 0.63 MAPT (0.41) MAPTTDP1SMN1; SMN2ALDH1A1
SCHEMBL28222341 0.61 MAPT (0.44) MAPTTDP1SMN1; SMN2ALDH1A1
SCHEMBL27856872 0.61 NISCH (0.34)
SCHEMBL4153725 0.60 MAPT (0.61) MAPTTDP1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101296699-A Pyrazolo [1, 5-a ] pyrimidine compounds MITSUBISHI TANABE PHARMA CORP (JP) 2008-10-29 CN claimed
CN-1073089-C Benzodiazepine derivatives, compositions thereof and their use in the manufacture of medicaments SHIONOGI & CO (JP) 2001-10-17 CN claimed
US-20010027247-A1 Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis G.D. SEARLE & CO., (US) 2001-10-04 US claimed
CN-103570693-B As the endocyclic compound of hepatitis c inhibitor and the application in medicine thereof SUNSHINE LAKE PHARMA CO.,LTD. (CN) 2015-10-14 CN disclosed
CN-102863428-B Spiro-compounds taken as hepatitis c virus (HCV) inhibitor GUANGDONG HEC PHARMACEUTICAL 2014-12-24 CN disclosed
CN-103570693-A Bridged compound serving as hepatitis C inhibitor and application of bridged compound in medicines GUANGDONG HEC PHARMACEUTICAL 2014-02-12 CN disclosed
CN-102863428-A Spiro-compounds taken as hepatitis c virus (HCV) inhibitor GUANGDONG HEC PHARMACEUTICAL 2013-01-09 CN disclosed
CN-101506221-B Estratriene derivatives and their use as 17 beta-hydroxysteroid dehydrogenase inhibitors SOLVAY PHARM BV 2012-09-12 CN disclosed
CN-101374843-B Triazolopyridazines as tyrosine kinase modulators JANSSEN PHARMACEUTICA NV 2012-09-05 CN disclosed
CN-101641117-B Pharmaceutical composition KYOWA HAKKO KIRIN CO LTD 2012-06-13 CN disclosed
CN-102414205-A Isoxazole-pyrazole derivatives HOFFMANN LA ROCHE 2012-04-11 CN disclosed
CN-1777590-A Indazole derivatives KYOWA HAKKO KOGYO KK (JP) 2006-05-24 CN disclosed
CN-1731994-A Prophylactic and therapeutic agent for neuropathy TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-02-08 CN disclosed
CN-1170827-C Benzofurylpyrone derivatives ������������ʽ���� 2004-10-13 CN disclosed
US-6613880-B2 Autoimmune diseases; inflammatory conditions; competitive binding with Human Leukocyte Antigen displacing disease-inducing endogenous peptides PHARMACIA CORPORATION 2003-09-02 US disclosed
US-20010027247-A1 Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis G.D. SEARLE & CO., (US) 2001-10-04 US disclosed
CN-1299359-A Benzofurylpyrone derivatives TEIJIN LTD (JP) 2001-06-13 CN disclosed
CN-1156440-A Method for producing acyloins BASF AG (DE) 1997-08-06 CN disclosed
WO-1996040753-A1 PIPECOLIC ACID DERIVATIVES OF PROLINE THREONINE AMIDES USEFUL FOR THE TREATMENT OF RHEUMATOID ARTHRITIS G.D. SEARLE & CO. (US) 1996-12-19 WO disclosed
CN-1064683-A New beta-amino-alpha-hydroxycarboxylic acids and uses thereof SANKYO CO (JP) 1992-09-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027247-A1 Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis ARGLU1, PRR12, PTMS MAPT 4124/4885TDP1 1172/4885SMN1; SMN2 4441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.